Nemolizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Nemolizumab |
| DrugBank ID | DB15252 |
| Brand Names (EU) | Nemluvio |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.55% |
Approved Indication (EMA)
Atopic dermatitis (AD) Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Prurigo nodularis (PN) Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | diabetic cataract | 98.55% | DL |
| 2 | diabetes mellitus type 2 associated cataract | 98.49% | DL |
| 3 | tetanic cataract | 98.49% | DL |
| 4 | immature cataract | 98.49% | DL |
| 5 | craniostenosis cataract | 98.49% | DL |
| 6 | mature cataract | 98.49% | DL |
| 7 | cortical cataract | 98.47% | DL |
| 8 | nuclear senile cataract | 98.47% | DL |
| 9 | senile cataract | 98.41% | DL |
| 10 | diabetic retinopathy | 98.24% | DL |
| 11 | severe nonproliferative diabetic retinopathy | 97.97% | DL |
| 12 | antithrombin deficiency type 2 | 97.71% | DL |
| 13 | factor 5 excess with spontaneous thrombosis | 97.65% | DL |
| 14 | heparin cofactor 2 deficiency | 97.59% | DL |
| 15 | thrombophilia | 97.31% | DL |
| 16 | diffuse gastric adenocarcinoma | 95.51% | DL |
| 17 | hemorrhagic disease of newborn | 95.25% | DL |
| 18 | gastric carcinoma | 94.83% | DL |
| 19 | gastric adenocarcinoma and proximal polyposis of the stomach | 94.83% | DL |
| 20 | bronchitis | 94.74% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.